{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-026757","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.113168+00:00","generated_at":"2026-06-12T11:20:26.850349+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept Q2 revenue $117.7M (+14% YoY); raises FY revenue guidance to $455-470M","bullets":["Revenue $117.7M, up 14% YoY; net income $27.5M ($0.25 diluted EPS) vs $27.4M ($0.24) in Q2 2022.","Raises FY 2023 revenue guidance to $455-470M from $435-455M; cash $363.3M.","Repurchased 6.6M shares for $145.4M in April 2023.","Clinical: GRACE Phase 3 enrollment complete; relacorilant NDA submission expected Q2 2024.","ROSELLA ovarian cancer trial enrollment on track to complete by end of 2023; Phase 2b NASH trial to start Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-026757","json":"https://secwatch.observer/filing/0001628280-23-026757.json","markdown":"https://secwatch.observer/filing/0001628280-23-026757.md","text":"https://secwatch.observer/filing/0001628280-23-026757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/0001628280-23-026757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/cort-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:20:26.850349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12e9be7d2d0cdd2be0f0f9b3a1710ae4f9a8b972","claim":"CORCEPT THERAPEUTICS INC reported the quarter ended June 30, 2023 results: revenue $117.7 million, net income $27.5 million, EPS $0.25 (diluted). Guidance raised.","evidence_excerpt":"metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Financial Results • Revenue of $117.7 million, a 14 percent increase from second quarter 2022 • Increase in 2023 revenue guidance to $455 – $470 million, from $435 – $455 million • Net income per common share of $0.25","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/0001628280-23-026757-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$117.7 million"},{"label":"Net income","value":"$27.5 million"},{"label":"EPS","value":"$0.25 (diluted)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}